Mirap (Mirtazapine)

Mirtazapine, the active ingredient in Mirap, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed to treat major depressive disorder in adult patients and modulates neurotransmitter activity, enhancing norepinephrine and serotonin signaling, which contributes to mood improvement clinically.

GNH USA supplies Mirap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Mirtazapine is a NaSSA antidepressant that acts on noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes associated with major depressive disorder: alleviates acute depressive symptoms during episodes. - Treatment‑resistant depression (adjunct therapy): may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior

When prescribing Mirap, clinicians should consider several safety measures.

- Assess hepatic function: evaluate liver enzymes before initiating therapy and monitor periodically. - Monitor weight and appetite: patients may experience significant weight gain. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Pregnancy and lactation: use only if benefit outweighs potential risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase drug exposure. - CNS depressants or alcohol: additive sedation and respiratory depression.